AI Article Synopsis
- The study aimed to analyze the long-term effectiveness and survival of biologic drugs used for psoriasis in real-world settings, rather than just clinical trials.
- Data was collected from 398 patients over a period from September 2005 to September 2014, utilizing Kaplan-Meier methods to assess 5-year survival rates for four biologics.
- Results showed that all biologics had decreasing survival rates over time, but ustekinumab had significantly higher survival rates compared to etanercept, adalimumab, and infliximab.
Article Abstract
Background/objectives: Data on biologic drug survival in real-world psoriasis treatment are limited. There is a need to evaluate long-term trends of biologic use outside the realm of clinical trials.
Methods: A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan-Meier plot analysis was used to determine 5-year drug survival rates. A log-rank test was used to compare the rates of drug survival between the studied biologics.
Results: For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5-year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics.
Conclusion: A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.12548 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!